XML 46 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Note 2 - Revenue (Tables)
12 Months Ended
Mar. 31, 2025
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Year Ended March 31, 2025

 
  

Sterilization and Disinfection Control (1)

  

Clinical Genomics

  

Biopharmaceutical Development

  

Calibration Solutions

  

Total

 

Consumables

 $82,736  $35,672  $17,287  $3,039  $138,734 

Hardware and Software

  496   7,689   19,649   31,827   59,661 

Services

  10,186   3,720   11,794   16,883   42,583 

Total revenues

 $93,418  $47,081  $48,730  $51,749  $240,978 
  

Year Ended March 31, 2024

 
  

Sterilization and Disinfection Control (1)

  

Clinical Genomics

  

Biopharmaceutical Development

  

Calibration Solutions

  

Total

 

Consumables

 $65,459  $36,086  $17,086  $2,345  $120,976 

Hardware and Software

  549   12,254   12,993   30,024   55,820 

Services

  9,116   4,248   10,633   15,394   39,391 

Total revenues

 $75,124  $52,588  $40,712  $47,763  $216,187 
  

Year Ended March 31, 2023

 
  

Sterilization and Disinfection Control

  

Clinical Genomics

  

Biopharmaceutical Development

  

Calibration Solutions

  

Total

 

Consumables

 $55,605  $43,374  $15,800  $3,062  $117,841 

Hardware and Software

  692   13,347   22,079   26,561   62,679 

Services

  8,312   5,578   9,486   15,184   38,560 

Total revenues

 $64,609  $62,299  $47,365  $44,807  $219,080 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Contract liabilities as of March 31, 2024

 $15,686 

Prior year liabilities recognized in revenues during the year ended March 31, 2025

  (9,873)

Contract liabilities added during the year ended March 31, 2025, net of revenues recognized

  8,990 

Contract liabilities balance as of March 31, 2025

 $14,803